474 related articles for article (PubMed ID: 33211212)
21. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
22. Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide.
Saag KG; Agnusdei D; Hans D; Kohlmeier LA; Krohn KD; Leib ES; MacLaughlin EJ; Alam J; Simonelli C; Taylor KA; Marcus R
Arthritis Rheumatol; 2016 Sep; 68(9):2122-8. PubMed ID: 27111239
[TBL] [Abstract][Full Text] [Related]
23. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
[TBL] [Abstract][Full Text] [Related]
24. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
25. Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Hagino H; Tanaka S; Kuroda T; Mori S; Soen S
J Bone Miner Metab; 2024 May; 42(3):382-388. PubMed ID: 38755328
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Bisphosphonates Versus Teriparatide in Therapy of the Glucocorticoid-Induced Osteoporosis (GIOP): A Meta-Analysis of Randomized Controlled Trials.
Dong B; Zhou Y; Wang J; Li C; Fu Z; Huang Y; Wang Y; Xu L
Horm Metab Res; 2023 Apr; 55(4):236-244. PubMed ID: 36652960
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
Ettinger B; San Martin J; Crans G; Pavo I
J Bone Miner Res; 2004 May; 19(5):745-51. PubMed ID: 15068497
[TBL] [Abstract][Full Text] [Related]
29. Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05.
Mori S; Hagino H; Sugimoto T; Tanaka S; Mitomo Y; Takahashi K; Sone T; Nakamura T; Soen S
Osteoporos Int; 2023 Jan; 34(1):189-199. PubMed ID: 36239756
[TBL] [Abstract][Full Text] [Related]
30. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide.
Takeuchi Y; Kuroda T; Sugimoto T; Shiraki M; Nakamura T
Calcif Tissue Int; 2016 Feb; 98(2):186-92. PubMed ID: 26478225
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
[TBL] [Abstract][Full Text] [Related]
32. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
33. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.
Nakamura T; Sugimoto T; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Yoshikawa H; Nishizawa Y; Fujita T; Shiraki M
J Clin Endocrinol Metab; 2012 Sep; 97(9):3097-106. PubMed ID: 22723322
[TBL] [Abstract][Full Text] [Related]
34. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
35. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
37. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide.
Tanaka S; Kuroda T; Sugimoto T; Nakamura T; Shiraki M
Curr Med Res Opin; 2014 May; 30(5):931-6. PubMed ID: 24392946
[TBL] [Abstract][Full Text] [Related]
38. Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05).
Tanaka S; Mori S; Hagino H; Sugimoto T
J Bone Miner Metab; 2020 May; 38(3):412-417. PubMed ID: 31894491
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
40. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Nakano T; Shiraki M; Sugimoto T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
J Bone Miner Metab; 2014 Jul; 32(4):441-6. PubMed ID: 24213216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
